[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Morten Ladekarl\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100503911","phase-2-gemcitabine-versus-reduced-dose-combination-chemotherapy-in-fragile-patients-with-non-resectable-pancreatic-cancer-100503911",false,"NCT05841420","Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer","A Randomized Phase II Study of Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Adenocarcinoma of the pancreas, histopathologically or cytologically verified\n* Non-resectable (locally advanced or metastatic) PC\n* Patients unfit or not candidate for full-dose combination chemotherapy\n* Patients eligible for full dose gemcitabine or reduced dose combination chemotherapy\n* Performance status (PS) ≤2\n* Measurable or non-measurable disease\n* Adequate hematologic function defined as absolute neutrophil count (ANC) ≥1.5 x 10\\^9\u002Fl and platelets count ≥100x10\\^9\u002Fl within 2 weeks prior to enrollment\n* Adequate organ function (bilirubin ≤1.5 x UNL (Upper Normal Limit) and eGFR (estimated Glomerular Filtration Rate) \\>50ml\u002Fmin within 2 weeks prior to enrollment\n* Toxicity of prior chemotherapy, including neurotoxicity, resolved to CTCAE \\\u003Cgrade 2\n* Oral and written informed consent must be obtained according to the local Ethics committee requirements\n* Fertile patients must use adequate contraceptives\n\nExclusion Criteria:\n\n* Patients eligible for downstaging\u002Fpreoperative chemotherapy followed by resection or local ablation or irradiation\n* Prior chemotherapy for PC (However, patients treated with adjuvant therapy with recurrence occurring more than 6 months after end of this treatment are eligible)\n* Concurrent, non-curatively treated malignant neoplasm other than pancreatic adenocarcinoma\n* Concurrent treatment with any other anti-cancer therapy\n* Pregnant or breast-feeding patients\n* Patients clearly intending to withdraw from the study if not randomized in the willing arm or patients who cannot be regularly followed up for psychological, social, familiar, or geographic reasons.\n* Other condition or therapy, which in the investigator's opinion may pose a risk to the patient or interfere with the study objectives.\n* Known allergy or intolerance to any of the drugs used in DPCG-01 (Gemcitabine, S1 or Nab-Paclitaxel)","ALL","18 Years",{"count":19,"type":20},98,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer, who are unfit for full-dose combination chemotherapy.\n\nThe patients will be equally randomized to arm A or arm B:\n\nArm A: Full-dose single agent treatment with Gemcitabine 1000 mg\u002Fm2 weekly on days 1, 8,and 15 every 4 weeks.\n\nArm B: Reduced-dose (80%) combination-treatment with Gemcitabine plus Nab-Paclitaxel (Gemcitabine: 800 mg\u002Fm2 plus Nab-Paclitaxel: 100 mg\u002Fm2 on day 1, 8 and 15 every 4 weeks)\n\nProgression-free survival, overall survival and response rate will be estimated for each group, as well as toxicity and quality of life will be prospectively registered.",[26,27],"Pancreas Cancer","Non-Resectable Pancreas Carcinoma",[29,30,31],"Fragile","Elderly","Palliative","RECRUITING","2025-01-27",{"date":35,"type":36},"2025-01-29","ACTUAL",{"date":38,"type":36},"2023-06-12",{"date":40,"type":20},"2025-06",{"name":42,"class":43},"Morten Ladekarl","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":44},"100492706","proseq-cancer-genomic-profiling-in-patients-with-incurable-cancer-in-search-for-targeted-treatment-100492706","NCT05695638","Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","Proseq Cancer: A Prospective Study of Comprehensive Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","Inclusion Criteria:\n\n* Incurable, progressing and\u002For life-threatening cancer\n* Expected residual survival of at least 3 months\n* No efficient remaining standard treatment options\n* Patient recruited from the Region of Northern Jutland, Denmark\n\nExclusion Criteria:\n\n* WHO Performance Status \\>2\n* Significant comorbidity, concurrent medication or laboratory values imposing an unacceptable risk at medical oncological treatment",{"count":53,"type":20},3000,"5 Years","OBSERVATIONAL","Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic data with the purpose of research, while fulfilling the Danish General Data Protection Regulation (GDPR) requirements. Patients are recruited from the North Denmark Region.\n\nTreatment can be offered on site if a targeted drug of a nationally approved indication is suggested by the national tumor board (NTB). If not, the patient may be treated in an available clinical protocol. If no approved drug or relevant protocol is available or feasible, treatment with a targeted drug used outside a clinical protocol is pursued.",[58,59],"Solid Tumor, Unspecified, Adult","Haematological Malignancy",[61,62,63,64],"Precision medicine","Personalized medicine","Genomic profiling","Tissue agnostic","2024-01-30",{"date":67,"type":36},"2024-01-31",{"date":69,"type":36},"2020-07-01",{"date":71,"type":20},"2035-05-31",{"name":42,"class":43},""]